SPIMA Therapeutics

SPIMA Therapeutics is a French biopharmaceutical company specializing in the development of innovative peptide-based therapeutics for oncology. The company leverages a proprietary platform to target the Myristoylated Alanine-Rich C-Kinase Substrate (MARCKS) protein, a key driver in cancer progression and therapeutic resistance. Their lead candidate is a cell-penetrating peptide designed to inhibit MARCKS, currently being evaluated for the treatment of glioblastoma and other aggressive solid tumors. Founded as a spin-off from the CNRS and the University of Montpellier, SPIMA aims to address significant unmet needs in the oncology space through its targeted peptide delivery technology. The company's approach focuses on disrupting intracellular signaling pathways that are often inaccessible to traditional small molecules or antibodies. SPIMA is currently advancing its lead programs through pre-clinical validation with the goal of entering clinical trials.